BioMimetic announces common stock public offering

BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) announced today a public offering of 5,000,000 shares of its common stock. BioMimetic has granted the underwriters an option to purchase up to an additional 15% of shares of common stock to cover over-allotments. BioMimetic expects to use the net proceeds of the offering for development and commercialization of its product pipeline and general corporate purposes.

J.P. Morgan Securities Inc. is acting as the sole lead book-running manager of the offering. Canaccord Genuity and Wedbush PacGrow Life Sciences will serve as co-managers. The offering will be made pursuant to a shelf registration statement that was previously filed with the Securities and Exchange Commission (the "SEC") and was declared effective on September 4, 2009.